Zealand Pharma A/S (Zealand) (CPH:ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced on Friday the return by Boehringer Ingelheim of an Amylin analog that was being developed for the treatment of obesity and Type 2 diabetes.
Reportedly, the Amylin analog programme was licensed to Boehringer Ingelheim in 2014 to conduct and finance all clinical development and commercialisation, with Zealand eligible to receive milestone payments and royalties on global sales.
As of 20 March 2020, this license agreement will no longer be active. The long-term partnership will continue with the license agreement to develop the GLP-1/glucagon analog BI 456906, which is planned to advance into phase 2 development.
Zealand added that it will communicate the potential of further development of the Amylin programme at a later stage, following a thorough evaluation.
Aptorum Group Teams with Covar Pharmaceuticals to Investigate at Least 3 Repurposed Drug Candidates
Seneca Biopharma names new president and chief operating officer, and chief financial officer
Alligator Bioscience temporarily halts recruitment of new patients due to COVID-19 pandemic
US FDA approves Sevenfact for treatment of adults and adolescents with haemophilia A or B
Arena Pharmaceuticals reveals positive top-line data from Phase one etrasimod clinical study
ElevateBio Raises USD 170m in Series B Financing
Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected 4Q20